343 related articles for article (PubMed ID: 31315834)
41. CircRNA microarray profiling identifies a novel circulating biomarker for detection of gastric cancer.
Tang W; Fu K; Sun H; Rong D; Wang H; Cao H
Mol Cancer; 2018 Sep; 17(1):137. PubMed ID: 30236115
[TBL] [Abstract][Full Text] [Related]
42. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
[TBL] [Abstract][Full Text] [Related]
43. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
[TBL] [Abstract][Full Text] [Related]
44. Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems.
Chang HR; Park HS; Ahn YZ; Nam S; Jung HR; Park S; Lee SJ; Balch C; Powis G; Ku JL; Kim YH
BMC Cancer; 2016 Mar; 16():200. PubMed ID: 26955870
[TBL] [Abstract][Full Text] [Related]
45. Circulating Tumor DNA Mutation Profiling by Targeted Next Generation Sequencing Provides Guidance for Personalized Treatments in Multiple Cancer Types.
Shu Y; Wu X; Tong X; Wang X; Chang Z; Mao Y; Chen X; Sun J; Wang Z; Hong Z; Zhu L; Zhu C; Chen J; Liang Y; Shao H; Shao YW
Sci Rep; 2017 Apr; 7(1):583. PubMed ID: 28373672
[TBL] [Abstract][Full Text] [Related]
46. Development of Patient-Derived Gastric Cancer Organoids from Endoscopic Biopsies and Surgical Tissues.
Gao M; Lin M; Rao M; Thompson H; Hirai K; Choi M; Georgakis GV; Sasson AR; Bucobo JC; Tzimas D; D'Souza LS; Buscaglia JM; Davis J; Shroyer KR; Li J; Powers S; Kim J
Ann Surg Oncol; 2018 Sep; 25(9):2767-2775. PubMed ID: 30003451
[TBL] [Abstract][Full Text] [Related]
47. A liquid biopsy signature predicts treatment response to fluoropyrimidine plus platinum therapy in patients with metastatic or unresectable gastric cancer: implications for precision oncology.
Lee IS; Zhu Z; Lee J; Park JO; Wu X; Ong T; Li SM; Wang X; Chao J; Goel A
Mol Cancer; 2022 Jan; 21(1):9. PubMed ID: 34980153
[No Abstract] [Full Text] [Related]
48. Identification of targeted therapy options for gastric adenocarcinoma by comprehensive analysis of genomic data.
Hescheler DA; Plum PS; Zander T; Quaas A; Korenkov M; Gassa A; Michel M; Bruns CJ; Alakus H
Gastric Cancer; 2020 Jul; 23(4):627-638. PubMed ID: 32107691
[TBL] [Abstract][Full Text] [Related]
49. Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes.
Kim JY; Lee E; Park K; Park WY; Jung HH; Ahn JS; Im YH; Park YH
Oncotarget; 2017 Apr; 8(17):27997-28007. PubMed ID: 28427202
[TBL] [Abstract][Full Text] [Related]
50. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
[TBL] [Abstract][Full Text] [Related]
51. Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial.
Cremolini C; Rossini D; Dell'Aquila E; Lonardi S; Conca E; Del Re M; Busico A; Pietrantonio F; Danesi R; Aprile G; Tamburini E; Barone C; Masi G; Pantano F; Pucci F; Corsi DC; Pella N; Bergamo F; Rofi E; Barbara C; Falcone A; Santini D
JAMA Oncol; 2019 Mar; 5(3):343-350. PubMed ID: 30476968
[TBL] [Abstract][Full Text] [Related]
52. Impact of Emergent Circulating Tumor DNA
Kim TW; Peeters M; Thomas A; Gibbs P; Hool K; Zhang J; Ang AL; Bach BA; Price T
Clin Cancer Res; 2018 Nov; 24(22):5602-5609. PubMed ID: 29898991
[No Abstract] [Full Text] [Related]
53. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy.
Ma F; Zhu W; Guan Y; Yang L; Xia X; Chen S; Li Q; Guan X; Yi Z; Qian H; Yi X; Xu B
Oncotarget; 2016 Oct; 7(40):66020-66031. PubMed ID: 27602761
[TBL] [Abstract][Full Text] [Related]
54. MET overexpression and amplification define a distinct molecular subgroup for targeted therapies in gastric cancer.
Yang Y; Wu N; Shen J; Teixido C; Sun X; Lin Z; Qian X; Zou Z; Guan W; Yu L; Rosell R; Liu B; Wei J
Gastric Cancer; 2016 Jul; 19(3):778-88. PubMed ID: 26404902
[TBL] [Abstract][Full Text] [Related]
55. Cytokeratin-18 fragments predict treatment response and overall survival in gastric cancer in a randomized controlled trial.
Nagel M; Schulz J; Maderer A; Goepfert K; Gehrke N; Thomaidis T; Thuss-Patience PC; Al-Batran SE; Hegewisch-Becker S; Grimminger P; Galle PR; Möhler M; Schattenberg JM
Tumour Biol; 2018 Mar; 40(3):1010428318764007. PubMed ID: 29534639
[TBL] [Abstract][Full Text] [Related]
56. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
Ji F; Liu X; Wu Y; Fang X; Huang G
Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
[TBL] [Abstract][Full Text] [Related]
57. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Catenacci DVT; Tebbutt NC; Davidenko I; Murad AM; Al-Batran SE; Ilson DH; Tjulandin S; Gotovkin E; Karaszewska B; Bondarenko I; Tejani MA; Udrea AA; Tehfe M; De Vita F; Turkington C; Tang R; Ang A; Zhang Y; Hoang T; Sidhu R; Cunningham D
Lancet Oncol; 2017 Nov; 18(11):1467-1482. PubMed ID: 28958504
[TBL] [Abstract][Full Text] [Related]
58. Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer.
Bataille F; Rümmele P; Dietmaier W; Gaag D; Klebl F; Reichle A; Wild P; Hofstädter F; Hartmann A
Mol Pathol; 2003 Oct; 56(5):286-92. PubMed ID: 14514923
[TBL] [Abstract][Full Text] [Related]
59. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial.
Fujitani K; Yang HK; Mizusawa J; Kim YW; Terashima M; Han SU; Iwasaki Y; Hyung WJ; Takagane A; Park DJ; Yoshikawa T; Hahn S; Nakamura K; Park CH; Kurokawa Y; Bang YJ; Park BJ; Sasako M; Tsujinaka T;
Lancet Oncol; 2016 Mar; 17(3):309-318. PubMed ID: 26822397
[TBL] [Abstract][Full Text] [Related]
60. Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer.
Tanioka M; Fan C; Parker JS; Hoadley KA; Hu Z; Li Y; Hyslop TM; Pitcher BN; Soloway MG; Spears PA; Henry LN; Tolaney S; Dang CT; Krop IE; Harris LN; Berry DA; Mardis ER; Winer EP; Hudis CA; Carey LA; Perou CM
Clin Cancer Res; 2018 Nov; 24(21):5292-5304. PubMed ID: 30037817
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]